Global Friedreich’s Ataxia Market, By Diagnosis (CT Scan or MRI Scan, Electromyography and Others), Treatment (Medication, Speech Therapy, Occupational Therapy, Surgeries, Others), Route of Administration (Oral, Parenteral and Others), End-Users (Clinics, Hospitals, Diagnostic Centers, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Friedreich’s Ataxia Market
Friedreich’s Ataxia market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 4.00% in the above-mentioned research forecast period. Rise in awareness about rare diseases and increase in geriatric population among others.
Technological advancements and the growing application of precision medicines also boost up the market growth. Moreover, increasing research and development, pipeline therapies, and rising healthcare expenditure act as an opportunity for market growth. But, the high cost associated with disease diagnosis and strict regulatory framework, among others, may hamper the Friedreich’s Ataxia market.
Friedreich’s Ataxia is characterized by difficulty walking, loss of sensation in the legs and arms, and impaired speech. It is also called spinocerebellar degeneration and has been described as an autosomal rare genetic disease. Friedreich’s Ataxia causes damage to the different parts of the brain and spinal cord and affects the heart. The different types of symptoms associated with this disease includes vision changes, weak muscles, difficulty in sensing legs and feet vibrations, lack of coordination, lack of reflexes, loss of hearing among others. As per the research conducted till now, Friedreich’s Ataxia affects 1 in every 40,000 people.
This disease is caused to mutation in the FXN gene, which codes for the protein frataxin, a protein required for mitochondria's proper functioning. As it is an autosomal recessive disease, the affected individual carries both the defective gene's copies while the disease has one normal and another abnormal FXN gene. Until now, no proper cure is available for the treatment of Friedreich’s Ataxia, but it can be managed up to an extent by applying physical therapy, speech therapy, occupational therapy, and surgery. Moreover, several drugs are under clinical trials indicated for the treatment of Friedreich’s Ataxia.
The research and development activities increasing for development of novel drugs indicated for treatment of several kinds of symptoms associated with Friedreich’s Ataxia. Moreover, different types of causes responsible for the inheritance of autosomal recessive disease are also increasing worldwide and are expected to provide the market with lucrative growth. It is also estimated that Friedreich’s Ataxia market was growing with a CAGR of 4% in 2020.
This Friedreich’s Ataxia market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Friedreich’s Ataxia Market Scope and Market Size
Friedreich’s Ataxia market is segmented on the basis of diagnosis, treatment, route of administration, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of diagnosis, the Friedreich’s Ataxia market is segmented into CT scan or MRI scan, electromyography and others.
- On the basis of treatment, the Friedreich’s Ataxia market is segmented into medication, speech therapy, occupational therapy, surgeries, others. Medication segment is further sub-segmented into beta blockers, ACE inhibitors, diuretics and others.
- On the basis of route of administration, the Friedreich’s Ataxia market is segmented into oral, parenteral and others.
- On the basis of end-users, the Friedreich’s Ataxia market is segmented into clinics, hospitals, diagnostic centers and others.
- On the basis of distribution channel, the Friedreich’s Ataxia market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, others.
Friedreich’s Ataxia Market Country Level Analysis
Friedreich’s Ataxia market is analysed and market size information is provided by country, diagnosis, treatment, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Friedreich’s ataxia market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts for the largest market share due to the rising awareness for Friedrich’s ataxia and increasing funding activities by the U.S. FDA to accelerate the research activities targeting rare diseases. Europe is also expected to grow due to rising initiative by market players and the rising number of orphan drug designations to a drug manufactured for occasional disease treatment.
For instance,
- In October 2017, Agilis Biotherapeutics, Inc. received orphan drug designation approval by the European Commission for its gene therapy product candidate AGIL-FA which has been developed for the treatment of Friedrich’s Ataxia.
Asia-Pacific is expected to account for the largest market share due to increasing patients focus towards effective disease diagnosis and increasing government focus towards the growth of pharmaceutical industries.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Friedreich’s Ataxia market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Friedreich’s Ataxia Market Share Analysis
Friedreich’s Ataxia market competitive landscape provides details by competitor details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Friedreich’s Ataxia market.
The major players covered in the Friedreich’s ataxia market are Reata Pharmaceuticals, Inc., Biovista, Adverum Biotechnologies Inc., Catabasis Pharmaceuticals Inc., RegenxBio, Pfizer Inc., ProQR Therapeutics, Agios Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., Watson Pharmaceuticals, Inc., Cipla, Dr. Reddy’s Laboratories Inc., HEMA PHARMACEUTICALS PVT. LTD., Bristol-Myers Squibb Company, Par Pharmaceutical, Sandoz AG, Sun Pharmaceuticals Industries Ltd., Lupin Pharmaceuticals, Inc., Sanofi, Lannett, GlaxoSmithKline plc, RPG Life Sciences Limited among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-
